Following an interim analysis Lundbeck's studies with bifeprunox for the treatment of schizophrenia is discontinued
H. Lundbeck A/S announced the joint decision with its partner Solvay Pharmaceuticals, B.V. to stop all joint R&D activities for Solvay's compound bifeprunox in development for maintenance treatment of schizophrenia.
The companies made this decision after evaluating the recent results from an interim analysis of pooled data intended for a possible extension of the ongoing clinical phase III trial programme. Efficacy data did not support pursuing the existing development strategy of stabilisation of non-acute patients with schizophrenia. Therefore, Lundbeck and Solvay judge that it would be futile to continue the studies.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Discovery of a protein that protects the brain from Alzheimer's disease - It is the LRP3 protein, which lowers the levels of two proteins involved in the formation of plaques in the brains of people with Alzheimer's disease.
